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EDITORIAL
The ten commandments for 
comprehensive heart failure 
management
The South African guidelines for the management of HFrEF 
also consider the role of invasive therapies – revascularisation, 
implantable cardioverter defibrillators (ICDs) and cardiac resyn-
chronisation therapy (CRT) by implantation of a biventricular 
pacemaker with (CRT-D) or without (CRT-P) an ICD, left 
ventricular assist device (LVAD) use and orthotopic heart 
transplantation – with a goal of ensuring efficient utilisation of 
these expensive therapies in a resource-limited environment. 
In addition, the role of additional management strategies – 
digoxin, the combination of hydralazine and nitrates, ivabradine, 
iron supplementation – is discussed and advice is provided on 
general preventive strategies (vaccinations). 
Importantly, the South African guidelines for the management 
of HFrEF discuss topics that are of great relevance to the patient 
with heart failure in sub-Saharan Africa – cardiomyopathy, 
rheumatic heart disease, HIV-associated cardiovascular disease, 
peripartum cardiomyopathy and atrial fibrillation – to improve 
clinical care for these entities that are common causes of heart 
failure in the region. 
The South African guidelines for the management of heart 
failure with a reduced ejection fraction (HFrEF) have been 
extensively updated and recently published.(1) The guidance is 
based upon the European Society of Cardiology Guidelines for 
the treatment of acute and chronic heart failure,(2) and sum-
marises the best current evidence for management of patients 
with heart failure.  It provides information on the definition, 
diagnosis, and epidemiology of HFrEF in the African context. 
Best evidence-based therapies for HFrEF are discussed, 
including established therapies – beta-blockers, angiotensin 
converting enzyme inhibitors (ACE-i), angiotensin receptor 
blockers (ARBs), mineralocorticoid receptor antagonists 
(MRAs), diuretics – that form the cornerstone of heart failure 
management. These revised guidelines also discuss novel 
therapies that have recently entered clinical use (angiotensin 
receptor-neprilysin inhibitor (ARNI), sodium/glucose cotrans-
porter-2 (SGLT2 inhibitors). 
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TABLE I: Essential principles of comprehensive heart 
failure management.
1.    HFrEF is heart failure with an ejection fraction <40% and diagnosis is 
suspected clinically followed by confi rmatory special investigations 
with a view to identify an underlying cause.
2.    Comprehensive HFrEF management involves numerous treatment 
modalities.
3.   Diuretics provide important symptomatic relief.
4.    Beta-blockers, ACE-inhibitors/ARBs and MRAs are the foundation of 
HFrEF management.
5.    Nitrate/hydralazine combination should be considered in black 
patients.
6.    Newer agents add incremental benefi t to more established heart 
failure therapies.
7.    There are useful adjunctive agents which improve quality of life for 
patients who remain symptomatic.
8.   Actively look for patients who will benefi t from device therapies.
9.    Management of atrial fi brillation is needed for many patients with 
HFrEF.
10.  Orthotopic heart transplantation remains an excellent treatment 

















Historical reports support the view that heart failure therapy is 
poorly implemented despite good evidence that adherence to 
clinical practice guidelines improves outcomes in patients with 
HFrEF.(3) Clinicians are encouraged to implement the recom-
mended interventions to improve both morbidity and mortality 
in heart failure patients. This requires patient education to 
promote adherence, overcoming clinical inertia to continue 
escalation of therapy to achieve comprehensive heart failure 
care as well as the necessary knowledge base of what treatment 
a patient can and should be offered.
In this brief article, we discuss 10 key areas of focus in heart 
failure management – see Table I. While there can be no 
substitute to read the actual guideline in its entirety, the 
following essential take-home messages are of relevance:
1.  HFrEF is heart failure with an ejection 
fraction <40% and diagnosis is suspected 
clinically followed by confi rmatory special 
investigations with a view to identify an 
underlying cause.
HFrEF is defined as presentation with symptoms and signs 
of heart failure in the presence of an ejection fraction of 
40% or less – see Table I I. Most practitioners will, however, 
implement HFrEF therapy at an ejection fraction cut-off of 
50% or less. Further diagnostic modalities are essential to 
confirm the diagnosis, rule out reversible causes of heart 
failure (valvular heart disease, pericardial constriction) and 
reversible causes of left ventricular dysfunction (hyperten-
sion, arrhythmia) and to assess the ejection fraction. Inves-
tigations helpful in this regard are the electrocardiography 
(ECG) – a normal ECG makes diagnosis of heart failure 
unlikely – and echocardiography. NT-pro-BNP, where 
available is also supportive, and an NT-proBNP <125pg/mL 
has a negative predictive value of the presence of heart 
failure of 94%. If there is still doubt after these investigations 
further imaging by cardiovascular magnetic resonance (CMR) 
is helpful – Figure 1. 
2.  Comprehensive HFrEF management involves 
numerous treatment modalities.
Once the diagnosis of HFrEF is established the patient should 
be commenced on evidence-based therapies which include 
lifestyle changes, pharmacological therapies, devices, and sur-
gical interventions – Figure 2. 
3.  Diuretics provide important 
symptomatic relief.
Loop diuretics are essential to manage the primary symptoms 
of heart failure congestion, even though they do not confer 
survival benefit. The aim is to maintain patients on the lowest 
possible dose that controls symptoms, and many patients 
will be able to titrate the dose themselves depending on 
their symptoms and/or sudden increases in body weight. 
4.  Beta-blockers, ACE-inhibitors/ARBs and MRAs 
are the foundation of HFrEF management.
The combination of beta-blockers, ACE-inhibitors/ARBs and 
MRAs forms the cornerstone of heart failure therapy. 
Morbidity and mortality benefit of these agents is well-
established in large randomised clinical trials (RCTs). It is 
essential to commence these three agents carefully, at a low 
dose, with the aim of gradually increasing in a stepwise 
fashion every 2 - 3 weeks to the maximally tolerated dose. 
The aim is to achieve the target dose as studied in various 
RCTs. Issues preventing patients from achieving optimal 
therapeutic disease include symptomatic hypotension, wors-
ening renal function, worsening symptoms of heart failure or 
significant bradycardia. 
5.  Nitrate/hydralazine combination should be 
considered in black patients.
The most underused therapy for patients with HFrEF in SSA 
is the combination of hydralazine and nitrates. This vaso-
dilator combination has been shown to have excellent 
mortality benefit, is well tolerated and has the additional 
advantage of being relatively safe to prescribe in pregnancy. 
TABLE II: Revised definition and classification of 
heart failure.








LVEF <40% LVEF 40% - 49% LVEF >50%
Elevated levels of 
natriuretic peptide 
(proBNP >125pg/ml or 
BNP >35pg/ml
At least 1 additional 
criterion:
• relevant structural 
heart disease (LVH and/
or LAE)
• diastolic dysfunction
Elevated levels of 
natriuretic peptide 
(proBNP >125pg/ml or 
BNP >35pg/ml
At least 1 additional 
criterion:
• relevant structural 
heart disease (LVH and/
or LAE)
•diastolic dysfunction
HFrEF = heart failure with reduced ejection fraction, HFmrEF = heart failure with 
mid-range ejection fraction, HFpEF = heart failure with preserved ejection fraction, 
LVEV = left ventricular ejection fraction, LAE = left atrial enlargement.
Adapted from Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and 
treatment of acute and chronic heart failure: The Task Force for the diagnosis and 
treatment of acute and chronic heart failure of the European Society of Cardiology 
(ESC). Developed with the special contribution of the Heart Failure Association (HFA) 
of the ESC. Eur Heart J 2016;37(27):2129-2200.
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FIGURE 1: Diagnosis of heart failure.
Medical history and physical examination are 










If electrocardiogram, echocardiogram and natriuretic peptides are normal and no suggestive 
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FIGURE 2: Principles of management of heart failure.
Goals of management of heart failure
Improve clinical status
Improve functional capacity


















Statin therapy for 







































10.  Orthotopic heart transplantation remains an 
excellent treatment modality for patients 
with HFrEF refractory to medical therapy.
Surgical therapy involves a big spectrum of procedures 
which include coronary revascularisation (in a select group 
of patients), percutaneous mitral valve repair and most 
importantly orthotopic heart transplantation. Heart trans-
plantation has excellent 10-year survival rates and should 
be considered in patients who deteriorate in terms of 
functional state despite adequate medical and device 
therapy.
In summary, there are numerous interventions that improve 
quality of life and increase survival in patients with HFrEF. The 
goals of comprehensive HFrEF therapy should be making a 
correct diagnosis, to ascertain the underlying cause of heart 
failure, to relieve symptoms, increase survival and to improve 
quality of life. Therefore, the importance of treating patients 
with all modalities that offer proven outcome benefit to achieve 
these goals cannot be overstated. At all times, every effort 
should be made to achieve guideline directed therapy.(4) 
However, it is important to remember that while guideline 
documents summarise the best clinical practice, they remain 
just what they are – guidelines. Therapy needs to be tailored to 
a given patient’s underlying clinical state, individual preferences, 
and social circumstances to achieve the best clinical outcome. 
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It should therefore strongly be considered in black patients 
with HFrEF in the peripartum period as well as in patients 
with ongoing symptoms despite beta-blockade, ACE-I/ARBs 
and MRAs use.
6.  Newer agents add incremental benefi t to 
more established heart failure therapies.
SGLT2 inhibitors and ARNI are agents that have recently 
been introduced in clinical practice in South Africa. These 
agents reduce cardiovascular death and hospitalisations for 
heart failure and all patients with HFrEF with ongoing symp-
toms should be considered candidates for these drugs. 
7.  There are useful adjunctive agents which 
improve quality of life for patients who remain 
symptomatic.
If patients remain symptomatic, the following agents can be 
added to the drugs already mentioned. Ivabradine, digoxin 
and intravenous iron (if a patient is iron deficient) are all 
useful adjunctive therapies that reduce heart failure hospital-
isation but have not been shown to reduce mortality. 
8.  Actively look for patients who will benefi t 
from device therapies.
Cardiac resynchronisation therapy with a biventricular 
pacemaker should be considered for patients with a QRS 
width broader than 150ms who remain in refractory heart 
failure despite maximally tolerated medical therapy. An 
internal cardioverter-defibrillator is indicated for patients 
who survive a sudden cardiac death and can be considered 
for primary prevention, especially if the patient has ischaemic 
left ventricular dysfunction. Left ventricular assist devices are 
expensive treatment modalities with a high complication 
rate – they should be considered in patients who need a 
bridge to transplantation, though they are increasingly used 
as destination therapy in many settings.
9.  Management of atrial fi brillation is needed for 
many patients with HFrEF.
Atrial fibrillation is the most common arrhythmia associated 
with HFrEF, and its presence denotes underlying structural 
heart disease. Anticoagulation remains by far the most 
important intervention to reduce the risk of thromboembolic 
events. Rate control is a reasonable initial strategy but in 
patients who are young or when the possibility of a 
tachycardia-induced cardiomyopathy is high, atrial fibrillation 
ablation may be of value. There should be a low threshold to 
refer patients with atrial flutter for radiofrequency ablation as 
the recurrence rate of this arrhythmia is high and rate control 
can be challenging.
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